CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
TAK-137 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02334982
NCT02334982Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects

Takeda·interventional·Posted Jan 9, 2015·Updated Feb 10, 2015

In Brief

A Phase 1 clinical trial evaluating TAK-137 and Placebo for Dose Finding Study. Completed, enrolled 47 participants.

Detailed Summary

The purpose of this study is to characterize the safety and tolerability profile of TAK-137 when administered as a single dose of tablets at escalating dose levels in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDose Finding Study
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 9, 2015
Enrollment StartJun 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.5 years ago

Interventions

TAK-137drug

TAK-137 tablets

Placebodrug

TAK-137 placebo-matching tablets